Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASA404 plus paclitaxel and carboplatin for first-line advanced non-small cell lung cancer
2007-006072-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ASA404 + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Overall survival. Started Apr 2008; status: completed.
02
Drugs
vadimezan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-006072-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006072-11.